

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A crystalline Form II of 17β -N-[2,5-bis (trifluoromethyl) phenyl] carbamoyl-4-aza-5- α -androst-1-en-3-one (dutasteride).

Claim 2 (original): The crystalline form of dutasteride of claim 1 having an X-ray powder diffraction pattern expressed in terms of d-spacing (in °A), said diffraction pattern includes peaks at about 13.42, 6.96, 6.13, 5.27, 4.77, 4.70, 4.58, 4.46 and 3.82.

Claim 3 (canceled)

Claim 4 (original): The crystalline form of dutasteride of claim 1 having an X-ray powder diffraction pattern substantially the same as shown in FIG. 2.

Claim 5 (original): The crystalline form of dutasteride of claim 1 having an infrared spectrum that includes peaks at about 818.56, 835.98, 1041.23, 1087.77, 1218.92, 1238.97, 1263.35, 1317.75, 1365.64, 1434.43, 1593.48, 1673.62, 2873.06, 2943.03, 3197.02, 3295.55, 3391.29, and 3449.55 cm^{-1} .

Claim 6 (original): A process for the preparation of crystalline Form II of dutasteride, said process comprising:

- (i) dissolving a crude form of dutasteride in an alcoholic solvent having from 1 to 5 carbon atoms;
- (ii) removing said alcoholic solvent thereby obtaining a residue;

- (iii) adding an ester solvent to said residue thereby obtaining a separated solid;
and
- (iv) filtering the separated solid that is said crystalline Form II of dutasteride.

Claim 7 (original): The process of claim 6, wherein said alcoholic solvent is methanol.

Claim 8 (original): The process of claim 6, wherein said ester solvent is ethyl acetate.

Claim 9 (original): The process of claim 6, further comprising drying said separated solid.

Claim 10 (currently amended): A process for the preparation crystalline Form I of dutasteride, said process comprising:

- (i) dissolving a crude dutasteride in a halogenated hydrocarbon solvent;
- (ii) removing said solvent thereby obtaining a residue;
- (iii) adding an aliphatic hydrocarbon solvent of low molecular [weight] to said residue thereby obtaining a separated solid; and
- (iv) filtering the separated solid that is said crystalline Form I of dutasteride.

Claim 11 (original): The process of claim 10, further comprising drying said separated solid.

Claim 12 (original): The process of claim 10, wherein said halogenated solvent is dichloromethane.

Claim 13 (original): The process of claim 10, wherein said aliphatic solvent is cyclohexane.

Claim 14 (original): An amorphous form of 17β -N-[2,5-bis (trifluoromethyl) phenyl] carbamoyl-4-aza-5- α -androst-1-en-3-one (dutasteride).

Claim 15 (currently amended): The amorphous form of dutasteride of claim 1[4] having an X-ray powder diffraction substantially the same as shown in FIG 4.

Claim 16 (currently amended): A process for preparation of novel amorphous form of dutasteride, said process comprising:

- (i) dissolving a crude form of dutasteride in an alcoholic solvent[[s]]
having from 1 to 5 carbon atoms;
- (ii) removing said alcoholic solvent to obtain a solid residue; [and]
- (iii) isolating said solid residue to afford the amorphous form of
dutasteride.

Claim 17 (original): The process of claim 16, wherein said alcoholic solvent is methanol.